Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (Drug Bank ID: DB13928, Chemical formula: C187H291N45O59) and tirzepatide (DB15171, C225H348N48O68), have become transformative agents in the management of type 2 diabetes mellitus (T2DM) and obesity due to their demonstrated benefits in glycemic control, weight loss, and potential cardiovascular protection [1,2,3,4]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.